How do you pay?

How to pay the least

Ask for the cash price

Fruzaqla

We didn’t find one.

  1. Ask your pharmacy for Fruzaqla’s cash price, and one or two other pharmacies too.
  2. Fruzaqla’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Takeda Oncology Patient Assistance Program (Takeda Oncology Here2Assist). To be eligible for the Patient Assistance Program, patients must meet certain financial and insurance coverage criteria. Or call 1-844-817-6468 (Option 2).

See if you qualify 

Compare every option

Question
Brand nameFruzaqla
Authorized genericfruquintinib
Regular genericfruquintinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Fruzaqla?
The original
–
–

Brand nameThe maker’s card

Takeda Oncology Co-Pay Assistance Program (Here2Assist)

Savings card from Takeda

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on fruzaqla.com 

Or call 1-844-817-6468.

In the maker’s words

“Commercially insured patients may pay as little as $0.00 for a 30-day prescription with the Takeda Oncology Co-pay assistance program.”

From the maker’s offer on fruzaqla.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Fruzaqla itself, from the same company, sold without the brand name, and usually for less. For now Fruzaqla is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.

Source: the FDA label for Fruzaqla (Takeda Pharmaceuticals America, Inc.), July 31, 2026. Full label on DailyMed 

Good to know